Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia : a retrospective single-center observation study

Inoue, Yuki; Kashiwagi, Hitoshi; Sato, Yuki et al.

International Journal of Clinical Pharmacy, 2024, 47(1), 90-98

Permalink : https://hdl.handle.net/2115/98585

このアイテムのアクセス数:50件（2026-07-14 04:21 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
huscap_98585_manuscript pdf 427 KB 34

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/98585
タイトル
Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia : a retrospective single-center observation study
著者
Inoue, Yuki ; Kashiwagi, Hitoshi ; Sato, Yuki ; Nashimoto, Shunsuke ; Sugawara, Mitsuru ; Takekuma, Yoh
著者名
Inoue, Yuki
e-Rad_Researcher
60510609
著者名
Kashiwagi, Hitoshi
著者名
Sato, Yuki
e-Rad_Researcher
40968525
著者名
Nashimoto, Shunsuke
e-Rad_Researcher
60332467
著者名
Sugawara, Mitsuru
e-Rad_Researcher
00396293
著者名
Takekuma, Yoh
言語
英語
キーワード
Adverse drug effects
Linezolid
Platelet count
Thrombocytopenia
発行日
2024-10-04
出版者
Springer
収録物名
International Journal of Clinical Pharmacy
巻(号)
47(1)
ページ
90-98
抄録
Background Patients treated with linezolid (LZD) frequently develop thrombocytopenia, and previous studies have identified the risk factors for this condition. However, the relationship between the development of LZD-induced thrombocytopenia and baseline platelet count has varied according to different reports. Aim To explore the relationship between platelet count and the development of LZD-induced thrombocytopenia. Method Patients who underwent LZD at Hokkaido University Hospital in Japan from September 2008 to March 2023 were included. We collected data on patient characteristics and platelet counts at baseline and during LZD therapy from the electronic medical records. Thrombocytopenia was defined as a decrease in platelet count by 30% or more from baseline, or a platelet level < 100,000/mu L. Results Two hundred and ninety-five patients who received LZD were included in this study, of whom 34.9% developed thrombocytopenia. In the early days of LZD treatment, the thrombocytopenia group showed a nearly 5% decrease in platelet count, while the non-thrombocytopenia group exhibited an increase of over 5%. Additionally, focusing on early onset thrombocytopenia (within 5 days), a baseline platelet count of < 150,000/mu L was identified as a risk factor for early thrombocytopenia. Conversely, it was also observed that 24.7% of patients with a baseline platelet count >= 150,000/mu L still developed early thrombocytopenia. Conclusion Our findings suggest that while a baseline platelet count of <150,000/mu L is a risk factor for the early onset of thrombocytopenia, vigilant monitoring of platelet counts by clinical pharmacists in the early stages of LZD treatment is essential, regardless of baseline platelet levels.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s11096-024-01810-1
PISSN
2210-7703
EISSN
2210-7711
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1007/s11096-024-01810-1